Concepedia

Ana M. Aparicio

AM

Statistics

Publications

90

Citations

7.9K

H-Index

47

Active since

1996

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Stanford University

University of Southern California

The University of Texas Health Science Center at Houston

University of California, San Francisco

Ana M. Aparicio is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, urology, and oncology.

ORCID

Top concepts

Publications per year

1996–2025

90

Publications

90

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Ana M. Aparicio, Andrea Harzstark, Paul G. Corn et al. · Clinical Cancer Research · 2013 · 456 citations · Full text

The Yeast Genome Directory

A Goffeau, R. Aert, M. L. Agostini-Carbone et al. · Nature · 1997 · 412 citations

, , +6

Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy

Shiping Jiao, Sumit K. Subudhi, Ana M. Aparicio et al. · Cell · 2019 · 373 citations

, , +11

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

Likun Li, Styliani Karanika, Guang Yang et al. · Science Signaling · 2017 · 293 citations · Full text

1–5 of 90